Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus TARGRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus TARGRETIN.
ALTRENO vs TARGRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
ALTRENO is not a recognized drug. No data available.
300 mg/m2 orally once daily.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Category C
Category C
Retinoid
Retinoid